Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. The poster presentation of the data was by Dr. Scott Tagawa , a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Veriheal

JANUARY 11, 2023

Gaize is mastering the art of cannabis impairment detection. The Missoula, Montana-based company is gearing up for the launch of its first science-backed real-time cannabis impairment detection device. Studies on cannabis have shown that the plant may cause disorientation, sedation, lack of concentration, and impaired judgment.

Clinical Trials 98

Clinical Trials THC Data Safety 98

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. These advanced analytics provide a human-centric, data-driven approach to phenotypic discovery for clients.”.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

AUGUST 22, 2022

Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. ” Dr. Gallow prides himself on his work as a South African cannabis advocate and leader in the international medical cannabis research field. It has been fairly slow,” explained Dr. Gallow.

Clinical Trials 113

Clinical Trials Chronic Pain Hydroponic Strains 113

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Eight studies were included, all of which are randomized controlled trials. 1.69, 95% CI [1.20–2.36])

Safety 52

Safety Cannabinoids Events Data 52

The Cannigma

FEBRUARY 2, 2021

This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Guy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 28, 2021

The ideal RPS has a strong technical background and is comfortable learning and navigating the online systems unique to various regulatory agencies, as well as other specialized technologies for research, clinical trials and project management. Experience working for a clinical study Sponsor. A master’s degree is preferred.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. Tim Moynahan the company chairman stated that “Patients in the MMJ International holdings clinical trials will receiv e gelatin capsules containing THC and CBD daily.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

Veriheal

APRIL 11, 2022

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Fortunately, the U.S. territories.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JANUARY 12, 2022

Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We We don’t believe safety and access are opposing polarities that must be constantly balanced.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Otherside Farms

JANUARY 25, 2019

“This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients. The findings have identified the potential for cannabinoids to reduce brain damage caused by stroke.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

JUNE 10, 2021

In short the study learns that legalized states tend not to have their roads overcrowded with stoned drivers and cannabis users like alcohol users self police their behaviour. The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Materials and methods.

Policy 59

Policy Safety Marijuana Data 59

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “We

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

JULY 30, 2019

Cannabis-based products will be allowed to bypass usual processes required for medicines in New Zealand and go directly onto the market without any proof of safety or effectiveness. This unprecedented proposal is contained in the government’s consultation document on giving greater access to medicinal cannabis.

Medicine 40

Medicine Clinical Trials Safety Access 40

Cannabis Law Report

JANUARY 31, 2022

The SAP is a federal program that allows healthcare professionals to apply for access to non-marketed medications that have not yet been approved for sale, when such medications show clinical evidence of safety and efficacy and are intended to treat patients with a severe or life-threatening illness.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

SEPTEMBER 20, 2021

TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp. Opticann medical cannabis products merge cannabis medicine with modern medicine. The products leverage pharmaceutical technology to maximize performance and safety. About Heritage Cannabis Holdings Corp.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

SEPTEMBER 12, 2022

The Company is working to supply various upcoming phase 1 & 2 clinical trials to build out the required human safety data in healthy Canadians, and eventually patients suffering from depression, anxiety, and PTSD. The harvest includes the following psilocybin-containing mushroom strains: Koh Samui. Penis Envy.

History 52

History Clinical Trials Legalization Research and Development 52

The Cannigma

AUGUST 31, 2021

Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. People want to trust their doctors, but doctors need knowledge. We have a ways to go,” Tan said.

Education 101

Education Clinical Trials Medicine Policy 101

Veriheal

JANUARY 5, 2023

A randomized, double-blind, cross-over trial of cannabis recently published by Research Gate explored whether or not cannabidiol (CBD) — the primary non-intoxicating constituent of cannabis and hemp — improves or reduces the cannabis safety. . of the planet’s population , consuming cannabis annually.

Clinical Trials 96

Clinical Trials Safety Consumption CBD 96

Cannabis Law Report

JULY 8, 2021

The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

The Cannigma

DECEMBER 14, 2021

This synthetic derivative of naturally occurring delta-9-Tetrahydrocannabinol (delta-9-THC) was first reported by noted cannabis chemist Professor Roger Adams at the University of Illinois in 1940. HHC was synthesized in Adams’ laboratory as part of research to understand the active compounds in the cannabis plant.

Research and Development 116

Research and Development Cannabinoids Clinical Trials THC 116

Veriheal

AUGUST 31, 2020

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

DECEMBER 26, 2021

EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. The Company is pleased to confirm that it is on track to submit its regulatory package to the Dutch ethics committee in early 2022 for its upcoming human trial.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Miss Marijuana

JUNE 30, 2019

Like a broken record we love to play, CBD research continues to find benefits in the cannabis product for chronic diseases, which then leads to better overall health and wellness! RELATED: I’m A Business Owner Who Uses Cannabis & CBD For Anxiety. So what exactly did researchers at CAHS find? So what’s next?

Sleep 72

Sleep CBD Clinical Trials Oil 72

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52